An emerging body of evidence indicates that the presence and functionality of Dendritic cells (DCs) within the tumor microenvironment are critical determinants of the efficacy of various immune checkpoint blockades and cancer therapies. The key concept of cancer immunotherapy is that the manipulation of the immune system can achieve cancer control and, ideally, a cure. To make immunotherapies more effective, it is crucial to comprehend how DCs trigger tumor immune responses and the strategies cancers use to avoid DC surveillance. Tumor-associated DCs have a significant potential for boosting antitumor responses, but their functional activity is generally compromised, and they may also contribute to immune suppression in cancer. The present understanding involved in human cancer by several DC subsets, emphasizing their function in T-cell priming, migration into tissues and the Tumor Microenvironment (TME), and coordinated in vivo responses. Furthermore, the present study could pave the way for the creation of novel therapeutic approaches that target DCs.